What is the appropriate starting dose, titration schedule, contraindications, and monitoring for lurasidone (Latuda) in adults with schizophrenia or bipolar depression?

Latuda (Lurasidone) Dosing and Management

Starting Dose and Titration

For adults with schizophrenia, start lurasidone at 40 mg once daily with no initial titration required; for bipolar depression, start at 20 mg once daily. 1

Schizophrenia Dosing

• Adults: Start 40 mg daily, effective range 40-160 mg/day, maximum 160 mg/day 1
• Adolescents (13-17 years): Start 40 mg daily, effective range 40-80 mg/day, maximum 80 mg/day 1
• No initial titration needed—therapeutic doses can be started immediately 1

Bipolar Depression Dosing

• Adults: Start 20 mg daily (monotherapy or adjunctive with lithium/valproate), effective range 20-120 mg/day 1
• Pediatric (10-17 years): Start 20 mg daily, may increase after one week based on response, maximum 80 mg/day 1
• Note: Higher doses (80-120 mg) showed no additional efficacy over lower doses (20-60 mg) in monotherapy studies 1

Recent evidence suggests that for acute schizophrenia with prominent positive symptoms or agitation, starting at 80 mg/day produces earlier symptom reduction without increased discontinuation rates 2. However, the FDA-approved starting dose remains 40 mg/day 1.

Critical Administration Requirement

Lurasidone MUST be taken with food containing at least 350 calories 1. This is non-negotiable—food increases absorption 2-fold (AUC) and 3-fold (Cmax) 1. Without food, patients receive subtherapeutic drug levels.

Dose Adjustments for Organ Impairment

Renal Impairment

• Moderate (CrCl 30-50 mL/min) or Severe (CrCl <30 mL/min): Start 20 mg/day, maximum 80 mg/day 1

Hepatic Impairment

• Moderate (Child-Pugh 7-9): Start 20 mg/day, maximum 80 mg/day 1
• Severe (Child-Pugh 10-15): Start 20 mg/day, maximum 40 mg/day 1

Drug Interactions Requiring Dose Modification

CYP3A4 Inhibitors (e.g., diltiazem, ketoconazole)

• Reduce lurasidone dose to half the original level 1
• Start at 20 mg/day, maximum 80 mg/day 1
• Strong CYP3A4 inhibitors are contraindicated 3

CYP3A4 Inducers (e.g., rifampin)

• May need to increase lurasidone dose 1
• Strong CYP3A4 inducers are contraindicated 3

Contraindications

Absolute contraindications 1:

• Concomitant use with strong CYP3A4 inhibitors (ketoconazole, clarithromycin, ritonavir)
• Concomitant use with strong CYP3A4 inducers (rifampin, phenytoin, carbamazepine)
• Known hypersensitivity to lurasidone

Black Box Warnings 1:

• Increased mortality in elderly patients with dementia-related psychosis (NOT approved for this indication)
• Increased risk of suicidal thoughts/behaviors in pediatric and young adults—requires close monitoring

Monitoring Requirements

Baseline Assessment

• Weight, BMI, waist circumference
• Fasting glucose and lipid panel
• Blood pressure
• Prolactin levels (if clinically indicated)
• ECG if cardiac risk factors present
• Assess for movement disorders

Ongoing Monitoring

• Weight: Monitor at weeks 4,8,12, then quarterly—lurasidone causes minimal weight gain compared to other antipsychotics 1, 4
• Metabolic parameters: Fasting glucose and lipids at 12 weeks, then annually (or more frequently if abnormal) 4
• Movement disorders: Assess for akathisia and parkinsonism at each visit, especially during dose escalation 4, 3
• Suicidality: Close monitoring in pediatric and young adult patients, particularly during initial treatment 1
• Prolactin: If symptoms of hyperprolactinemia develop (galactorrhea, amenorrhea, sexual dysfunction) 5

Common Adverse Effects to Monitor

The most frequent side effects are somnolence, akathisia, nausea, and parkinsonism 4, 3. Akathisia is dose-related and more common at higher doses 3.

Special Populations

Pregnancy

Exercise caution, particularly in first trimester 6. Weigh risks versus benefits carefully.

Elderly

Consider lower dose range (20-80 mg/day) with careful monitoring 6. Remember the black box warning regarding dementia-related psychosis 1.

Duration of Treatment

The FDA label notes that effectiveness beyond 6 weeks has not been established in controlled studies 1. Periodically re-evaluate long-term usefulness for individual patients 1. However, this reflects study duration limitations rather than evidence of declining efficacy.

Optimal Dosing Based on Recent Evidence

For bipolar depression, a 2024 meta-analysis found that 40-60 mg daily (optimal around 50 mg) provides the best balance of efficacy and tolerability 5. Side effects increase at higher doses without proportional efficacy gains 5. Weight gain occurs at doses <60 mg but glucose elevation occurs at doses >70 mg 5.